{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:33Z","timestamp":1793296113939,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal fibrosis (RF) represents the most widespread pathological condition in chronic kidney disease (CKD). Recently, protein prenylation has been implicated in the fibrosis\u2019s progression. The research examined the renoprotective effect of zoledronic acid (ZA) (50\u00a0\u00b5g\/kg\/week) in a rat model of carbon tetrachloride (CCl<jats:sub>4<\/jats:sub>)-induced RF through targeting protein prenylation. Forty Wistar male rats were split up into the control group, vehicle-treated group, model-RF group, and RF-ZA group. Mean arterial blood pressure (MBP), BUN, serum creatinine, and urine albumin\u2013creatinine ratio (uACR), protein levels of farnesyl pyrophosphate (FPP), tumour necrosis factor-alpha (TNF-\u03b1), transforming growth factor-\u03b2 (TGF-\u03b2), and malondialdehyde (MDA), and catalase and gene expression of farnesyl pyrophosphate synthase (FPPS) and nuclear factor-kB (NF-\u03baB) were measured. Immunohistochemical staining for renal interleukin-6 (IL-6), \u03b1-smooth muscle actin (\u03b1-SMA), and caspase-3, as well as histopathological alterations, were assessed. ZA considerably ceased the reduction in MBP, markedly reduced uACR, serum creatinine, BUN, and expression of FPPS, FPP, NF-\u03baB, TGF-\u03b2, TNF-\u03b1, and MDA, and significantly increased catalase levels compared to the model-RF rats. ZA ameliorated the CCl<jats:sub>4<\/jats:sub>-induced histopathological alterations and suppressed the expression of caspase-3, \u03b1-SMA, and IL-6. In conclusion, ZA preserved renal function and prevented renal fibrosis in a rat model. These were achieved through targeting protein prenylation mainly by inhibiting FPPS.<\/jats:p>","DOI":"10.1038\/s41598-024-68303-z","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:05:25Z","timestamp":1723003525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of protein prenylation inhibition through targeting FPPS by zoledronic acid in the prevention of renal fibrosis in rats"],"prefix":"10.1038","volume":"14","author":[{"given":"Reham Hussein","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina S.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesma Hussein Abdel","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesma Mohamed","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa Karem M.","family":"M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia Ahmed Yousef","family":"Yehia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia M.","family":"AbdelMaksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yomna M.","family":"Tamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"68303_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","volume":"8","author":"R Huang","year":"2023","unstructured":"Huang, R., Fu, P. & Ma, L. Kidney fibrosis: From mechanisms to therapeutic medicines. Sig. Transduct. Target Ther. 8, 129. https:\/\/doi.org\/10.1038\/s41392-023-01379-7 (2023).","journal-title":"Sig. Transduct. Target Ther."},{"issue":"2","key":"68303_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.23876\/j.krcp.22.159","volume":"42","author":"C Wang","year":"2023","unstructured":"Wang, C., Li, S. W., Zhong, X., Liu, B. C. & Lv, L. L. An update on renal fibrosis: From mechanisms to therapeutic strategies with a focus on extracellular vesicles. Kidney Res. Clin. Pract. 42(2), 174\u2013187. https:\/\/doi.org\/10.23876\/j.krcp.22.159 (2023).","journal-title":"Kidney Res. Clin. Pract."},{"key":"68303_CR3","unstructured":"Vaidya, S. R. & Aeddula, N. R. Chronic Kidney Disease. [Updated 2022 Oct 24]. In StatPearls [Internet]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535404\/ (StatPearls Publishing, Treasure Island (FL), 2024)."},{"key":"68303_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2021.106073","author":"CY Ung","year":"2021","unstructured":"Ung, C. Y., Onoufriadis, A., Parsons, M., McGrath, J. & Shaw, T. Metabolic perturbations in fibrosis disease. Int. J. Biochem. Cell Biol. https:\/\/doi.org\/10.1016\/j.biocel.2021.106073 (2021).","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"68303_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1039\/c9md00442d","volume":"11","author":"P Manaswiyoungkul","year":"2019","unstructured":"Manaswiyoungkul, P., de Araujo, E. D. & Gunning, P. T. Targeting prenylation inhibition through the mevalonate pathway. RSC Med. Chem. 11(1), 51\u201371. https:\/\/doi.org\/10.1039\/c9md00442d (2019).","journal-title":"RSC Med. Chem."},{"key":"68303_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.nbt.2012.07.001","volume":"30","author":"MK Dhar","year":"2013","unstructured":"Dhar, M. K., Koul, A. & Kaul, S. Farnesyl pyrophosphate synthase: A key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development. New Biotechnol. 30, 114\u2013123. https:\/\/doi.org\/10.1016\/j.nbt.2012.07.001 (2013).","journal-title":"New Biotechnol."},{"issue":"6","key":"68303_CR7","doi-asserted-by":"publisher","first-page":"9593","DOI":"10.3892\/mmr.2017.7798","volume":"16","author":"D Jiang","year":"2017","unstructured":"Jiang, D., Chen, Y., Zhu, Y., Fu, G. & Xu, S. Expression of key enzymes in the mevalonate pathway are altered in monocrotaline-induced pulmonary arterial hypertension in rats. Mol. Med. Rep. 16(6), 9593\u20139600. https:\/\/doi.org\/10.3892\/mmr.2017.7798 (2017).","journal-title":"Mol. Med. Rep."},{"issue":"8","key":"68303_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.bbalip.2010.03.014","volume":"1801","author":"GP Hooff","year":"2010","unstructured":"Hooff, G. P., Wood, W. G., M\u00fcller, W. E. & Eckert, G. P. Isoprenoids, small GTPases and Alzheimer\u2019s disease. Biochim. Biophys. Acta 1801(8), 896\u2013905. https:\/\/doi.org\/10.1016\/j.bbalip.2010.03.014 (2010).","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"68303_CR9","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1042\/BSR20140021","volume":"34","author":"L Tong","year":"2014","unstructured":"Tong, L. & Tergaonkar, V. Rho protein GTPases and their interactions with NF\u03baB: Crossroads of inflammation and matrix biology. Biosci. Rep. 34(3), e00115. https:\/\/doi.org\/10.1042\/BSR20140021 (2014).","journal-title":"Biosci. Rep."},{"key":"68303_CR10","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T. et al. NF-\u03baB signaling in inflammation. Sig. Transduct. Target Ther. 2, 17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23 (2017).","journal-title":"Sig. Transduct. Target Ther."},{"issue":"6","key":"68303_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/cells9061348","volume":"9","author":"S White","year":"2020","unstructured":"White, S., Lin, L. & Hu, K. NF-\u03baB and tPA signaling in kidney and other diseases. Cells 9(6), 1348. https:\/\/doi.org\/10.3390\/cells9061348 (2020).","journal-title":"Cells"},{"issue":"4","key":"68303_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/mmr.2023.12980","volume":"27","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Mechanism of dioscin ameliorating renal fibrosis through NF-\u03baB signaling pathway-mediated inflammatory response. Mol. Med. Rep. 27(4), 93. https:\/\/doi.org\/10.3892\/mmr.2023.12980 (2023).","journal-title":"Mol. Med. Rep."},{"key":"68303_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.899469","author":"L Tanner","year":"2022","unstructured":"Tanner, L. et al. Zoledronic acid targeting of the mevalonate pathway causes reduced cell recruitment and attenuates pulmonary fibrosis. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.899469 (2022).","journal-title":"Front. Pharmacol."},{"key":"68303_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172469","author":"RH Mohamed","year":"2019","unstructured":"Mohamed, R. H., Tarek, M., Hamam, G. G. & Ezzat, S. F. Zoledronic acid prevents the hepatic changes associated with high fat diet in rats; the potential role of mevalonic acid pathway in nonalcoholic steatohepatitis. Eur. J. Pharmacol. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172469 (2019).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"68303_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5114\/aoms.2016.60227","volume":"14","author":"\u0130U Sert","year":"2018","unstructured":"Sert, \u0130U. et al. The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: A light and electron microscopy study. Arch. Med. Sci. 14(2), 381\u2013387 (2018).","journal-title":"Arch. Med. Sci."},{"issue":"11","key":"68303_CR16","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","volume":"33","author":"CW Fixen","year":"2022","unstructured":"Fixen, C. W. & Fixen, D. R. Renal safety of zoledronic acid for osteoporosis in adults 75\u00a0years and older. Osteoporos. Int. 33(11), 2417\u20132422. https:\/\/doi.org\/10.1007\/s00198-022-06499-4 (2022).","journal-title":"Osteoporos. Int."},{"issue":"16","key":"68303_CR17","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/bph.15193","volume":"177","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 177(16), 3617\u20133624. https:\/\/doi.org\/10.1111\/bph.15193 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"68303_CR18","unstructured":"Novartis Pharmaceuticals Australia Pty Ltd. Aclasta product information. (2009)."},{"issue":"3","key":"68303_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies. FASEB J. 22(3), 659\u2013661 (2008).","journal-title":"FASEB J."},{"issue":"6","key":"68303_CR20","first-page":"624","volume":"4","author":"P Sengupta","year":"2013","unstructured":"Sengupta, P. The laboratory rat: Relating its age with human\u2019s. Int. J. Prev. Med. 4(6), 624\u2013630 (2013).","journal-title":"Int. J. Prev. Med."},{"issue":"1","key":"68303_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1258\/002367791780808121","volume":"25","author":"K Doi","year":"1991","unstructured":"Doi, K., Kurabe, S., Shimazu, N. & Inagaki, M. Systemic histopathology of rats with CCl4-induced hepatic cirrhosis. Lab. Anim. 25(1), 21\u201325 (1991).","journal-title":"Lab. Anim."},{"key":"68303_CR22","doi-asserted-by":"publisher","first-page":"107117","DOI":"10.1016\/j.intimp.2020.107117","volume":"90","author":"Ma Jie-Qiong","year":"2021","unstructured":"Jie-Qiong, Ma., Zhang, Y.-J., Tian, Z.-K. & Liu, C.-M. Bixin attenuates carbon tetrachloride induced oxidative stress, inflammation and fibrosis in kidney by regulating the Nrf2\/TLR4\/MyD88 and PPAR-\u03b3\/TGF-\u03b21\/Smad3 pathway. Int. Immunopharmacol. 90, 107117. https:\/\/doi.org\/10.1016\/j.intimp.2020.107117 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"68303_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25(4), 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"68303_CR24","first-page":"126","volume-title":"Bancroft\u2019s Theory and Practice of Histological Techniques","author":"KS Survarna","year":"2013","unstructured":"Survarna, K. S., Layton, C. & Bancroft, J. D. Bancroft\u2019s Theory and Practice of Histological Techniques 8th edn, 126\u2013138 (Churchill Livingstone, Elsevier, 2013).","edition":"8"},{"issue":"10","key":"68303_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.febslet.2015.03.015","volume":"589","author":"WB Chen","year":"2015","unstructured":"Chen, W. B. et al. GGPPS deficiency aggravates CCl4-induced liver injury by inducing hepatocyte apoptosis. FEBS Lett. 589(10), 1119\u20131126. https:\/\/doi.org\/10.1016\/j.febslet.2015.03.015 (2015).","journal-title":"FEBS Lett."},{"issue":"3","key":"68303_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/10409238.2018.1458070","volume":"53","author":"A Jeong","year":"2018","unstructured":"Jeong, A., Suazo, K. F., Wood, W. G., Distefano, M. D. & Li, L. Isoprenoids and protein prenylation: Implications in the pathogenesis and therapeutic intervention of Alzheimer\u2019s disease. Crit. Rev. Biochem. Mol. Biol. 53(3), 279\u2013310. https:\/\/doi.org\/10.1080\/10409238.2018.1458070 (2018).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"11","key":"68303_CR27","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc.2016.76","volume":"16","author":"PJ Mullen","year":"2016","unstructured":"Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nat. Rev. Cancer 16(11), 718\u2013731 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"68303_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/cvr\/cvs347","volume":"97","author":"J Yang","year":"2013","unstructured":"Yang, J. et al. Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice. Cardiovasc. Res. 97, 490\u2013499. https:\/\/doi.org\/10.1093\/cvr\/cvs347 (2013).","journal-title":"Cardiovasc. Res."},{"issue":"52","key":"68303_CR29","doi-asserted-by":"publisher","first-page":"36204","DOI":"10.1074\/jbc.M114.593285","volume":"289","author":"JL Larson-Casey","year":"2014","unstructured":"Larson-Casey, J. L., Murthy, S., Ryan, A. J. & Carter, A. B. Modulation of the mevalonate pathway by Akt regulates macrophage survival and development of pulmonary fibrosis. J. Biol. Chem. 289(52), 36204\u201336219 (2014).","journal-title":"J. Biol. Chem."},{"key":"68303_CR30","doi-asserted-by":"publisher","first-page":"39186","DOI":"10.1038\/srep39186","volume":"6","author":"CZ Zhao","year":"2016","unstructured":"Zhao, C. Z. et al. Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodeling. Sci. Rep. 6, 39186. https:\/\/doi.org\/10.1038\/srep39186 (2016).","journal-title":"Sci. Rep."},{"issue":"15","key":"68303_CR31","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1074\/jbc.REV119.008897","volume":"295","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Wu, T. Y., Zhao, M. F. & Li, C. J. The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. J. Biol. Chem. 295(15), 5152\u20135162. https:\/\/doi.org\/10.1074\/jbc.REV119.008897 (2020).","journal-title":"J. Biol. Chem."},{"key":"68303_CR32","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.3390\/cells10113057","volume":"10","author":"B Jiao","year":"2021","unstructured":"Jiao, B. et al. STAT6 deficiency attenuates myeloid fibroblast activation and macrophage polarization in experimental folic acid nephropathy. Cells 10, 3057. https:\/\/doi.org\/10.3390\/cells10113057 (2021).","journal-title":"Cells"},{"issue":"1","key":"68303_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jcp.30574","volume":"237","author":"C An","year":"2022","unstructured":"An, C. et al. Myeloid PTEN deficiency aggravates renal inflammation and fibrosis in angiotensin II-induced hypertension. J. Cell. Physiol. 237(1), 983\u2013991. https:\/\/doi.org\/10.1002\/jcp.30574 (2022).","journal-title":"J. Cell. Physiol."},{"issue":"12","key":"68303_CR34","doi-asserted-by":"publisher","first-page":"735014","DOI":"10.3389\/fimmu.2021.735014","volume":"26","author":"B Jiao","year":"2021","unstructured":"Jiao, B. et al. Pharmacological inhibition of STAT6 ameliorates myeloid fibroblast activation and alternative macrophage polarization in renal fibrosis. Front. Immunol. 26(12), 735014. https:\/\/doi.org\/10.3389\/fimmu.2021.735014 (2021).","journal-title":"Front. Immunol."},{"issue":"17","key":"68303_CR35","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1111\/bph.16096","volume":"180","author":"C An","year":"2023","unstructured":"An, C. et al. Jumonji domain-containing protein-3 (JMJD3) promotes myeloid fibroblast activation and macrophage polarization in kidney fibrosis. Br. J. Pharmacol. 180(17), 2250\u20132265. https:\/\/doi.org\/10.1111\/bph.16096 (2023).","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"68303_CR36","doi-asserted-by":"publisher","first-page":"e8955","DOI":"10.1371\/journal.pone.0008955","volume":"5","author":"AB Sanz","year":"2010","unstructured":"Sanz, A. B. et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: Modulation of CCL21. PLoS\u00a0One 5(1), e8955. https:\/\/doi.org\/10.1371\/journal.pone.0008955 (2010).","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"68303_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000094780","volume":"26","author":"S Patel","year":"2006","unstructured":"Patel, S. et al. Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am. J. Nephrol. 26(4), 381\u2013387. https:\/\/doi.org\/10.1159\/000094780 (2006).","journal-title":"Am. J. Nephrol."},{"key":"68303_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fphar.2017.00473","volume":"8","author":"Z Ma","year":"2017","unstructured":"Ma, Z. et al. Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-\u03b21 signaling. Front. Pharmacol. 8, 473 (2017).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"68303_CR39","doi-asserted-by":"publisher","first-page":"F596","DOI":"10.1152\/ajprenal.00365.2015","volume":"310","author":"A Sureshbabu","year":"2016","unstructured":"Sureshbabu, A., Muhsin, S. A. & Choi, M. E. TGF-\u03b2 signaling in the kidney: Profibrotic and protective effects. Am. J. Physiol. Renal Physiol. 310(7), F596\u2013F606. https:\/\/doi.org\/10.1152\/ajprenal.00365.2015 (2016).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"68303_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ebiom.2018.04.023","volume":"31","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Runt-related transcription factor 1 (RUNX1) promotes TGF-\u03b2-induced renal tubular epithelial-to-mesenchymal transition (EMT) and renal fibrosis through the PI3K subunit p110\u03b4. EBioMedicine 31, 217\u2013225 (2018).","journal-title":"EBioMedicine"},{"key":"68303_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3892\/etm.2021.9655","volume":"3","author":"H Xu","year":"2021","unstructured":"Xu, H. et al. Inhibition of the mevalonate pathway improves myocardial fibrosis. Exp. Ther. Med. 3, 224. https:\/\/doi.org\/10.3892\/etm.2021.9655 (2021).","journal-title":"Exp. Ther. Med."},{"key":"68303_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07164-x","volume":"20","author":"A G\u00f6bel","year":"2020","unstructured":"G\u00f6bel, A. et al. Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. BMC Cancer 20, 1\u201317 (2020).","journal-title":"BMC Cancer"},{"key":"68303_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cbi.2018.03.003","volume":"286","author":"JQ Ma","year":"2018","unstructured":"Ma, J. Q., Liu, C. M. & Yang, W. Protective effect of rutin against carbon tetrachloride-induced oxidative stress, inflammation and apoptosis in mouse kidney associated with the ceramide, MAPKs, p53 and calpain activities. Chem. Biol. Interact. 286, 26\u201333. https:\/\/doi.org\/10.1016\/j.cbi.2018.03.003 (2018).","journal-title":"Chem. Biol. Interact."},{"key":"68303_CR44","doi-asserted-by":"publisher","first-page":"e87410","DOI":"10.1371\/journal.pone.0087410","volume":"9","author":"RG Fu","year":"2014","unstructured":"Fu, R. G. et al. Inhibition of the K+ channel K(Ca)3.1 reduces TGF-\u03b21-induced premature senescence, myofibroblast phenotype transition and proliferation of mesangial cells. PLoS\u00a0One 9, e87410 (2014).","journal-title":"PLoS\u00a0One"},{"key":"68303_CR45","doi-asserted-by":"publisher","first-page":"e110365","DOI":"10.1371\/journal.pone.0110365","volume":"9","author":"B Oujo","year":"2014","unstructured":"Oujo, B. et al. L-endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction. PLoS\u00a0One 9, e110365 (2014).","journal-title":"PLoS\u00a0One"},{"issue":"4","key":"68303_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1165\/rcmb.2019-0296OC","volume":"62","author":"DM Santos","year":"2020","unstructured":"Santos, D. M. et al. Screening for YAP inhibitors identifies statins as modulators of fibrosis. Am. J. Respir. Cell Mol. Biol. 62(4), 479\u2013492 (2020).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"68303_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6197219","author":"K Leiya","year":"2022","unstructured":"Leiya, K., Pei, K., Guangwei, L. & Shuang, W. Progress of statin therapy in the treatment of idiopathic pulmonary fibrosis. Oxidative Med. Cell. Longev. https:\/\/doi.org\/10.1155\/2022\/6197219 (2022).","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"2","key":"68303_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/immuno2020021","volume":"2","author":"A Sheridan","year":"2022","unstructured":"Sheridan, A., Wheeler-Jones, C. P. D. & Gage, M. C. The immunomodulatory effects of statins on macrophages. Immuno 2(2), 317\u2013343. https:\/\/doi.org\/10.3390\/immuno2020021 (2022).","journal-title":"Immuno"},{"issue":"10","key":"68303_CR49","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneph.2012.191","volume":"8","author":"HM Wadei","year":"2012","unstructured":"Wadei, H. M. & Textor, S. C. The role of the kidney in regulating arterial blood pressure. Nat. Rev. Nephrol. 8(10), 602\u2013609 (2012).","journal-title":"Nat. Rev. Nephrol."},{"issue":"4","key":"68303_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/era.13.15","volume":"13","author":"D Isla","year":"2013","unstructured":"Isla, D., Afonso, R., Bosch-Barrera, J. & Mart\u00ednez, N. Zoledronic acid in lung cancer with bone metastases: A review. Expert Rev. Anticancer Ther. 13(4), 421\u2013426. https:\/\/doi.org\/10.1586\/era.13.15 (2013).","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"18","key":"68303_CR51","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356(18), 1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"68303_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen, S. et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 74(5), 641\u2013648. https:\/\/doi.org\/10.1038\/ki.2008.193 (2008).","journal-title":"Kidney Int."},{"issue":"2","key":"68303_CR53","doi-asserted-by":"publisher","first-page":"555757","DOI":"10.19080\/JOJCS.2018.09.555757","volume":"9","author":"S Bouomrani","year":"2018","unstructured":"Bouomrani, S., Rega\u00efeg, N., Nefoussi, M. & Trabelsi, S. Zoledronic acid-induced acute renal failure in multiple myeloma. JOJ Case Stud. 9(2), 555757. https:\/\/doi.org\/10.19080\/JOJCS.2018.09.555757 (2018).","journal-title":"JOJ Case Stud."},{"key":"68303_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2015.04.016","author":"R Bergner","year":"2015","unstructured":"Bergner, R., Siegrist, B., Gretz, N., Pohlmeyer-Esch, G. & Kr\u00e4nzlin, B. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy. Pharmacol. Res. https:\/\/doi.org\/10.1016\/j.phrs.2015.04.016 (2015).","journal-title":"Pharmacol. Res."},{"key":"68303_CR55","first-page":"1676","volume":"349","author":"C JT","year":"2004","unstructured":"JT, C. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349, 1676\u20131679 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"7\u20138","key":"68303_CR56","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.1E589","volume":"39","author":"A Munier","year":"2005","unstructured":"Munier, A. et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann. Pharmacother. 39(7\u20138), 1194\u20131197 (2005).","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"68303_CR57","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella, M. A. & Markowitz, G. S. Bisphosphonate nephrotoxicity. Kidney Int. 74(11), 1385\u20131393 (2008).","journal-title":"Kidney Int."},{"issue":"5","key":"68303_CR58","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","volume":"16","author":"S Pozzi","year":"2011","unstructured":"Pozzi, S. & Raje, N. The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future. Oncol. 16(5), 651\u2013662 (2011).","journal-title":"Oncol."},{"issue":"18","key":"68303_CR59","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","volume":"15","author":"S Pozzi","year":"2009","unstructured":"Pozzi, S. et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin. Cancer Res. 15(18), 5829\u20135839. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0426 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"68303_CR60","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.1038\/s41598-021-87375-9","volume":"11","author":"FRN de Sousa","year":"2021","unstructured":"de Sousa, F. R. N. et al. The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats. Sci. Rep. 11(1), 7672. https:\/\/doi.org\/10.1038\/s41598-021-87375-9 (2021).","journal-title":"Sci. Rep."},{"issue":"6","key":"68303_CR61","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/cre2.643","volume":"8","author":"MQS Soares","year":"2022","unstructured":"Soares, M. Q. S. et al. High doses of zoledronic acid induce differential effects on femur and jawbone microstructure. Clin. Exp. Dent. Res. 8(6), 1487\u20131495. https:\/\/doi.org\/10.1002\/cre2.643 (2022).","journal-title":"Clin. Exp. Dent. Res."},{"key":"68303_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2015.05.015","author":"PG Barros Silva","year":"2015","unstructured":"Barros Silva, P. G. et al. Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis. Arch. Oral Biol. https:\/\/doi.org\/10.1016\/j.archoralbio.2015.05.015 (2015).","journal-title":"Arch. Oral Biol."},{"issue":"4","key":"68303_CR63","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/app11041906","volume":"11","author":"MY Shaheen","year":"2021","unstructured":"Shaheen, M. Y. et al. Effect of systemic zoledronic acid dosing regimens on bone regeneration in osteoporotic rats. Appl. Sci. 11(4), 1906. https:\/\/doi.org\/10.3390\/app11041906 (2021).","journal-title":"Appl. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68303-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68303-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T09:12:48Z","timestamp":1725268368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68303-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68303"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68303-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18283"}}